Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 28.7% in March

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 242,174 shares, an increase of 28.7% from the February 26th total of 188,218 shares. Based on an average trading volume of 188,709 shares, the days-to-cover ratio is currently 1.3 days. Approximately 4.9% of the company’s stock are sold short.

Evogene Stock Up 4.8%

Shares of EVGN opened at $0.77 on Wednesday. Evogene has a twelve month low of $0.72 and a twelve month high of $2.42. The stock has a market capitalization of $4.13 million, a P/E ratio of -0.66 and a beta of 1.36. The company has a 50 day moving average of $0.91 and a 200-day moving average of $1.07.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Saturday, February 14th. The biotechnology company reported ($0.61) EPS for the quarter. The business had revenue of $0.31 million during the quarter. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.

Hedge Funds Weigh In On Evogene

A number of large investors have recently modified their holdings of EVGN. Jane Street Group LLC grew its holdings in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,387 shares in the last quarter. Citadel Advisors LLC raised its holdings in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Evogene during the fourth quarter valued at approximately $25,000. 10.40% of the stock is currently owned by institutional investors and hedge funds.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.